| |
|
|
|
Enlivex Therapeutics Ltd  
|
|
14.89 -0.4 (-0.03%) |
03-01 16:00 |
|
Open: |
16.2 |
Pre close: |
15.29 |
Target:
|
26.24
|
|
High: |
16.375 |
Low: |
14.6 |
Resistance:
|
22.46
29.40
|
|
Volume: |
343,412 |
Market Cap: |
271M |
Support:
|
11.24
9.35
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
15.38
 |
MACD |
MACD(12,26):
|
0.60 |
|
MA(20): |
17.65  |
Signal(12,26,9): |
1.40 |
|
MA(100): |
12.12 |
Stochastic Oscillator |
%K(14,3):
|
10.99 |
|
MA(250): |
8.07 |
%D(3): |
13.33 |
|
Average Volume(K) |
3-Month: |
55456
|
52-Week |
High:
|
29.40 |
|
10-Days: |
55503 |
Low: |
3.59 |
|
RSI |
RSI(14):
|
46.21 |
Change(%): |
113.9 |
|
Financials, Statistics and Valuation |
|
EPS |
-0.740 |
Return on Equity (ttm) |
-41.8 |
Shares Out. (M) |
13.46 |
|
EPS Est. Current Year |
0.000 |
Return on Assets (ttm) |
-21.2 |
Shares Float (M) |
8.19 |
|
EPS Est. Next Year |
0.000 |
PEG Ratio |
0.00 |
% Held by Insiders |
33.52 |
|
EPS Est. Next Quarter |
0.000 |
Qtrly Rev. Growth |
0.0 |
% Held by Institutions |
13.47 |
|
Forward EPS |
-1.400 |
Gross Profit (p.s.) |
0.000 |
Shares Short (K) |
217 |
|
Book Value (p.s.) |
2.120 |
EBITDA (p.s.) |
-0.645 |
P/E |
-20.12 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
7.02 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-6.90 |
P/S |
0.00 |
|
Operating Margin |
0.00 |
Levered Free Cash Flow
(M) |
-4.04 |
P/CF |
-29.05 |
|
|
|
|
|
|
